Skip to main
AAPG

AAPG Stock Forecast & Price Target

AAPG Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ascentage Pharma Group is positioned for success, based on its strong financial standing, partnerships, and potential revenue growth from its promising drugs in pipeline, including Olverembatinib and Lisaftoclax, which have shown positive results in clinical trials for treating blood cancers and solid tumors. Challenges in the form of slower adoption and delays in drug launches may arise, but the company's diversified pipeline and promising partnerships, such as with Takeda, make it a solid candidate for potential financial gains and further market success in both the United States and China.

Bears say

Ascentage Pharma Group is a clinical-stage biotechnology company with a focus on developing therapies for cancers and other diseases. Despite having promising drug candidates in their pipeline, the company faces competition from established players in the market, limiting potential growth. Additionally, enrollment or regulatory delays for their drug candidate lisaftoclax may push back launch timelines. While the company is already seeing success in China, scaling their commercial efforts and securing partnerships with more favorable economics will be key for sustained long-term growth.

AAPG has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ascentage Pharma Group International and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ascentage Pharma Group International (AAPG) Forecast

Analysts have given AAPG a Strong Buy based on their latest research and market trends.

According to 5 analysts, AAPG has a Strong Buy consensus rating as of Jun 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ascentage Pharma Group International (AAPG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.